Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome

NCT04369469 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04369469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04369469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome
Lead sponsor
Alexion Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
May 10, 2020
Completion date
April 8, 2021
Enrollment
202 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

acute lung injury, acute respiratory distress syndrome, covid-19 severe pneumonia, pneumonia, viral